Iovance stock sank after phase 2 Amtagvi lung cancer data. Read more here. Rasi Bhadramani/iStock via Getty Images - Iovance Biotherapeutics (IOVA) is down ~34% in Thursday trading after releasing data for two cohorts of a phase 2 trial of Amtagvi (lifileucel) for…
An experimental drug that Genmab gained in an $8 billion buyout succeeded in a late-stage trial in a form of head and neck cancer, sending shares of the Danish drugmaker soaring to an all-time high. At an early analysis, a combination…
/PRNewswire/ -- Frost & Sullivan is pleased to announce that Indegene has received the 2026 Global Enabling Technology Leadership Recognition in pharma... Indegene is recognized for combining domain-led AI, knowledge orchestration, and integrated execution to transform pharmaceutical commercialization workflows. SAN ANTONIO, Oct. 22, 2026 /PRNewswire…
Oops, something went wrong U.S. markets close in 5h 42m Alnylam Pharmaceuticals Q3 Non-GAAP Net Income, Revenue Rise; Fiscal 2026 Net Product Sales Outlook Kept Alnylam Pharmaceuticals (ALNY) reported Q3 non-GAAP net income Thursday of $16.26 per diluted share, up from $3.19 a year earlier. Alnylam: Q2 Earnings Snapshot…
Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity…
Nov 19, 2025, 08:06 ET Good Growth Capital together with Meach Cove Capital and other Global Investors Support Next Commercial Milestone Following Successful Honeybee Vaccine Launch; Dalan's European Subsidiary Receives Additional €250K Grant for Pan European Surveillance of Honeybee Diseases As part of the…
A new review proposes a conditional treatment sequence for Waldenström macroglobulinemia, from frontline options to choices after covalent BTK inhibitor exposure.
Genmab A/S (GMAB) reported positive results form a Phase 3 trial evaluating Petosemtamab plus Keytruda (pembrolizumab) as a first-line treatment for patients with PD-L1 positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival and tumor…
2026-10-28. The following slide deck was published by AstraZeneca PLC in conjunction with this event.
Interested in Genmab A/S Sponsored ADR? Here are five stocks we like better. Genmab reported three positive Phase III readouts for EPKINLY in first-line diffuse large B-cell lymphoma, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and…
The largest biotech companies - Amgen, Gilead, Regeneron, Vertex, Biogen, Moderna, BioNTech, Alnylam, Argenx - and their pipelines, results and strategy.
An article joins this feed when it matches these terms. Each one is also a search of its own.